At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Nivolumab in pediatric patients exhibiting a high mutational load.
Choosing to participate in an early patient access program is an important personal decision.
Talk with your doctor and family members or friends about deciding to join an early patient
To learn more about early patient access programs, your doctor may contact BMS using the
information provided below.
Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an "accelerated" basis for some types of cancer. Please contact your physician for more details.
Other Name: Array
Specific eligibility criteria must be met for access outside of a clinical trial.
These inclusion criteria include:
- The illness must be serious or life threatening
- There are no other viable options (including approved products or active clinical
- There is sufficient evidence that the potential benefit to the patient would likely
outweigh the potential risks based on what is known at the time
- Other defined inclusion/exclusion criteria could be applicable.
Bristol-Myers Squibb, Study Director